Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.36 |
| ▸ | TPX2 | Q9ULW0 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 7/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016924 | 0.81 | MAPT (0.40) | DGAT1MAPTNPC1 | |
| SCHEMBL2015933 | 0.75 | NPC1 (0.43) | DGAT1MAPTNPC1 | |
| SCHEMBL17967614 | 0.74 | MAPT (0.39) | DGAT1MAPTNPC1CCNCCDK8 | |
| SCHEMBL1427439 | 0.73 | CHEK1 (0.39) | MAPTNPC1 | |
| SCHEMBL20744453 | 0.71 | DGAT1 (0.38) | DGAT1AURKAAURKBINCENPTPX2 | |
| SCHEMBL16608588 | 0.71 | DGAT1 (0.40) | DGAT1BRD4 | |
| SCHEMBL29870445 | 0.71 | DGAT1 (0.38) | DGAT1AURKAAURKBINCENPTPX2 | |
| SCHEMBL8181971 | 0.70 | BRD4 (0.46) | DGAT1AURKAAURKBINCENPTPX2 | |
| SCHEMBL1427629 | 0.70 | MAPT (0.36) | DGAT1MAPTMETNPC1BRD4 | |
| SCHEMBL1427695 | 0.70 | DGAT1 (0.33) | DGAT1MAPTMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2300475-B1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH INC (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2706059-A1 | Diazacarbazoles and methods of use | Genentech, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300475-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | DGAT1 1960/4885AURKA 44/4885AURKB 20/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | DGAT1 3239/4885AURKA 2074/4885AURKB 1069/4885 |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | DGAT1 3239/4885AURKA 2074/4885AURKB 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.